CIP
DGX icon

Capital Insight Partners’s Quest Diagnostics DGX Stock Holding History

Capital Insight Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,168
Closed -$377K – 26
2025
Q4 		$377K Sell
2,168
-146
-6% -$26.6K 0.08% 111
2025
Q3 		$441K Buy
2,314
+314
+16% +$55.7K 0.07% 138
2025
Q2 		$359K Buy
+2,000
New +$347K 0.06% 141

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Capital Insight Partners's DGX Position: Q1 2026 in Review

Capital Insight Partners sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 2,168 shares — an estimated $377K sold.

Capital Insight Partners first reported a position in DGX in Q2 2025 and held it in 3 quarters. The position peaked at $441K in Q3 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Capital Insight Partners reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Capital Insight Partners sold 2,168 Quest Diagnostics shares in Q1 2026, an estimated $377K.
  • Capital Insight Partners first reported a position in Quest Diagnostics in Q2 2025 and held it in 3 quarters.
  • Capital Insight Partners's Quest Diagnostics position peaked at $441K in Q3 2025.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Capital Insight Partners's 13F filing for Q1 2026.